Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Lupin shares tumble as...

    Lupin shares tumble as CCI imposes Rs 73 crore fine

    Written by savita thakur thakur Published On 2016-08-03T12:20:07+05:30  |  Updated On 3 Aug 2016 12:20 PM IST
    Lupin shares tumble as CCI imposes Rs 73 crore fine

    NEW DELHI: Shares of Lupin ended in the negative territory after the Competition Commission imposed a penalty of Rs 73 crore on the company and its two officials for indulging in unfair business practices with regard to supply of medicines in Karnataka.


    Lupin has been asked to pay a penalty of Rs 72. 96 crore, accounting for 1 per cent of its average turnover for three years starting from 2011-12.


    Company's two officials - Amit Kumar Dhiman and Nishant Ajmera - have been fined Rs 5,117 and Rs 8,393, respectively, as per the CCI order.


    Shares of Lupin opened at Rs 1,747.80, then plunged to an intra-day low of Rs 1,698.05 on the BSE.


    On the NSE, the stock opened at Rs 1,741, then fell to an intra-day low of Rs 1,697.


    Lupin spokesperson had said the company would be looking at legal resources, including filing an appeal against the order passed by the Competition Commission of India (CCI).


    Together, the regulator has imposed a total fine of little over Rs 73 crore on six entities -- Lupin, KCDA and four individuals.


    They have also been directed to "cease and desist" from anti-competitive practices. KCDA has been penalised Rs 8.6 lakh while its two officials - A K Jeevan and D S Guddodgi - have been fined Rs 56,055 and Rs 4.5 lakh, respectively.


    In its order dated July 28, CCI said KCDA restrained pharmaceutical companies from appointing new stockists in Karnataka unless a No-Objection Certificate (NoC) was obtained from it.


    Further, it was found that Lupin also refused to supply drugs to the complainant in the absence of NoC.

    Amit Kumar DhimanCompetition Commission of IndiaFine on LupinLupinNishant Ajmerapharma newsRs 73 crore fine
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok